Combining ATRA and Sphingomyelin to Treat Melanoma
Author Information
Author(s): İŞLEK KÖKLÜ Zeynep, ŞANVERDİ Elif Lidya, KARADAĞ Başak, ÜÇIŞIK Mehmet Hikmet, TAŞKAN Ezgi, ŞAHİN Fikrettin
Primary Institution: Department of Genetics and Bioengineering, Yeditepe University, İstanbul, Turkiye
Hypothesis
The concurrent use of all-trans retinoic acid (ATRA) and sphingomyelin (SM) will enhance the effectiveness of anticancer treatment in B16F10 melanoma cells.
Conclusion
The combination of ATRA and SM significantly reduces the viability of melanoma cells while improving safety for healthy cells.
Supporting Evidence
- The combination of ATRA and SM showed a 50% reduction in cell proliferation.
- Combinational treatment resulted in 53.91% apoptotic cell death in melanoma cells.
- Gene expression levels of CASP3 and Bax increased significantly with the combination treatment.
- Cell cycle analysis indicated G2/M phase arrest after treatment with ATRA and SM.
Takeaway
Using two medicines together can help fight skin cancer better than using just one. This study shows that combining ATRA and SM can kill more cancer cells while being safer for healthy cells.
Methodology
The study investigated the effects of ATRA and SM on B16F10 melanoma cells through cell viability, apoptosis, cell cycle analysis, and gene expression levels.
Limitations
The study was conducted in vitro, and further research is needed to confirm findings in vivo.
Statistical Information
P-Value
p ≤ 0.0001
Statistical Significance
p ≤ 0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website